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 3 
Abstract 4 
Objective: The aim of this work was to assess baseline serum levels of established biomarkers 5 
related to inflammation and oxidative stress in nearly 200 serum samples from AKU subjects 6 
enrolled in SONIA1 and SONIA2 clinical trials (DevelopAKUre project). 7 
Methods: Levels of Serum Amyloid A (SAA), IL-6, IL-1β, TNFα, CRP, cathepsin D, IL-1ra, and 8 
MMP-3 were determined through commercial ELISA assays. Chitotriosidase activity was assessed 9 
through a fluorimetric method. Adavnced Oxidation Protein Products (AOPP) were determined by 10 
spectrophotometry. Thiols, S-thiolated proteins and Protein Thiolation Index (PTI) were determined 11 
by spectrophotometry and HPLC. Patients’ quality of life was assessed through validated 12 
questionnaires. 13 
Results: We found that SAA serum levels were significantly increased compared to reference 14 
threshold in 57.5% and 86% of the analysed samples in SONIA1 and SONIA2, respectively. 15 
Similarly, chitotriosidase activity was above the reference range in half of the tested SONIA2 16 
samples, whereas CRP levels were increased only in a minority of the tested AKU subjects. AOPP, 17 
thiols, S-thiolated protein and PTI showed no differences from control population. We provided 18 
evidence that AKU patients presenting with significantly higher SAA, chitotriosidase activity and 19 
PTI reported more often a decreased quality of life. This suggests that worsening of symptoms in 20 
AKU is paralleled by increased inflammation and oxidative stress, which might play a role in 21 
disease progression. 22 
Conclusions: Monitoring of SAA may be suggested in AKU to evaluate inflammation. Though 23 
further evidence is needed, SAA, chitotriosidase activity and PTI might be proposed as disease 24 
activity markers in AKU. 25 
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2 
1 Introduction 29 
Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder (MIM 203500) causing an 30 
early onset, chronically debilitating spondylo-arthropathy due to high circulating homogentisic acid 31 
(HGA, 2,5-dihydroxyphenylacetic acid) [1]. Accumulation of HGA is due to mutations of the HGD 32 
gene causing the production of a defective HGD enzyme in tyrosine and phenilalanine catabolic 33 
pathways [2]. Excess HGA is partly eliminated in the urine, partly contributes to the production of 34 
an ochronotic pigment deposited in cartilagineous tissues, which leads to a range of clinical 35 
manifestations. AKU causes considerable morbidity in adulthood, and cases of acute fatal 36 
metabolic complications (oxidative haemolysis and/or methaemoglobinaemia) were reported [3]. 37 
So far, no correlation between genotype and HGA circulating levels has been found.  38 
AKU still lacks appropriate biomarkers to monitor progression excepting for an AKU Severity Score 39 
Index (AKUSSI) [4]. The use of nitisinone (NTBC) was suggested in AKU to lower circulating HGA 40 
levels, and clinical trials were undertaken in Europe (DevelopAKUre - Clinical Development of 41 
Nitisinone for Alkaptonuria) [5]. Recent evidence pointed out also that AKU is a multisystem 42 
disease involving secondary (AA) amyloidosis due to high circulating Serum Amyloid A (SAA) 43 
promoting inflammation, oxidative stress and amyloidosis [6, 7]. The presence of SAA and Serum 44 
Amyloid P (SAP) in in vitro and ex vivo AKU models highlighted the amyloid nature of ochronotic 45 
pigment [6, 8, 9]. So far, AA amyloid has been reported in AKU in several tissues: 46 
a. cartilage [9-11] 47 
b. synovia [9, 11] 48 
c. cardiac valve [8, 12] 49 
d. salivary gland [11] 50 
and high circulating levels of SAA have been found in a small cohort of Italian AKU patients [6, 8, 51 
9, 13]. Furthermore, HGA-induced oxidative stress was highlighted in AKU [6-8, 13-19]. 52 
In this framework, we undertook this work to monitor the presence of established biomarkers 53 
related to inflammation and oxidative stress in serum of a high number of AKU subjects who 54 
were/are enrolled in DevelopAKUre clinical trials. 55 
 56 
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2 Material and Methods 57 
2.1 Samples 58 
This study was carried out as a part of the inflammatory and oxidative marker analysis of 59 
DevelopAKUre project [5] for SONIA1 (Suitability of Nitisinone in Alkaptonuria 1), and SONIA2 60 
(Suitability of Nitisinone in Alkaptonuria 2) clinical studies. In SONIA1, serum samples were 61 
collected from 40 AKU subjects under fasting conditions at baseline (i.e., when they first entered 62 
the study) at the investigative sites of Liverpool (UK) and Piešt'any (SK). Details on 63 
inclusion/exclusion criteria can be found in [5]. Serum samples from healthy volunteers were 64 
collected at Siena University Hospital and used as controls. Demographics of SONIA1 AKU and 65 
control cohorts are reported in Table 1S. 66 
In SONIA2, serum samples were collected from 138 AKU subjects under fasting conditions at 67 
baseline at the investigative sites of Liverpool (UK), Piešt'any (SK) and Paris (F). Demographics of 68 
SONIA2 patients are reported in Table 2S. 69 
  70 
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2.3 ELISA 71 
Assays for pro-inflammatory markers were carried out by means of commercial ELISA kits 72 
according to manufacturer’s instruction, as follows: SAA (KHA0012), IL-1β (KHC0011), IL-6 73 
(KHC0062); TNFα (KHC3013), CRP (KHA0031), MMP-3 (KAC1541) (all from Invitrogen-Life 74 
Technologies), CATD (ab119586, abcam), IL-1ra (KAC1181, BioSource Europe). Plates were read 75 
on a VersaMax microplate reader (Molecular Devices) using Ascent software (Thermo Scientific). 76 
Quantification of analytes was obtained against polynomial standard curves generated with 77 
appropriate standards. 78 
2.4 Laboratory tests 79 
Cholesterol and triglycerides were determined through an enzymatic colorimetric method, and 80 
HDL-cholesterol and LDL-cholesterol were determined through a homogeneous enzymatic 81 
colorimetric method on a Cobas® 6000, Roche/Hitachi cobas c system. Serum HGA levels were 82 
previously determined in [5]. 83 
2.5 Serum chitotriosidase activity assay 84 
Chitotriosidase activity was determined according to [20]. Briefly, 2.5 µL of serum were incubated 85 
with 50 µL of 22 µM 4-methylumbelliferyl-l-β-D-N,N',N"-triacetylchitotriose (Sigma) in Mcllvain's 86 
phosphate-citrate buffer (pH 5.2) for 1 hour at 37°C. Reactions were terminated by adding 1.4 mL 87 
of 0.2 M glycine buffer (pH 10.8); fluorescence of 4-methylumbelliferone was read in a fluorimeter 88 
(Perkin Elemer; excitation 365 nm, emission 435 nm). 89 
2.6 Advanced Oxidation Protein Products 90 
AOPP were measured according to [21] by spectrophotometry on a microplate reader (VersaMax, 91 
Molecular Devices) using Softmax Pro software (Molecular Devices). Calibration was performed 92 
with chloramine-T (Sigma) solutions that in the presence of potassium iodide absorb at 340 nm. 93 
Blank wells were prepared with 200 μL of PBS; standard wells were prepared with 200 μL of 94 
chloramine-T solution (range 5–100 μmol/L); test wells were prepared with 200 μL of serum 95 
samples diluted 1:10 or 1:20 in PBS. Then, 10 μL of 1.16 M potassium iodide (Sigma) was added 96 
5 
to each well followed 2 minutes later by bolus addition of acetic acid (20 μL). The chloramine-T 97 
absorbance was immediately read at 340 nm; being linear within the range of 0 to 100 μmol/L, 98 
AOPP concentrations were expressed as micromoles per litre of chloramine-T equivalents. 99 
2.7 Thiols, S-thiolated proteins and Protein Thiolation Index (PTI) 100 
Quantitative determination of free thiols and S-thiolated proteins (used to calculate PTI) in serum 101 
samples was carried out according to [22]. Briefly, one aliquot of serum (0.03 mL) was used to 102 
measure thiol levels by colorimetric reaction with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) [23]. 103 
One additional aliquot of serum (0.1 mL) was treated with 0.1 mL of 2 mM N-ethylmaleimide (NEM, 104 
dissolved in 0.2 M phosphate buffer pH 7.4) for 2 min and then deproteinized by addition of 18 µl of 105 
60% (w/v) trichloroacetic acid (TCA). This second aliquot of serum was used to measure the level 106 
of S-thiolated proteins. 107 
The content of mixed disulfides between low molecular mass thiols and protein thiols (S-thiolated 108 
proteins) was determined by HPLC after release of the protein-bound thiols with dithiotreitol (DTT) 109 
and their labeling with monobromobimane (mBrB) [24]. The protein pellet obtained by 110 
centrifugation at 10,000g for 2 min was washed three times with 1.5% (w/v) TCA, in order to 111 
remove excess NEM and free low molecular mass thiols. Then, it was resuspended by gyratory 112 
shaking with 400 µl of 1 mM K3EDTA containing 16 µl of 50 mM DTT and 15 µl of 2 M Tris [15]. 113 
Supernatants (0.1 mL) were then spiked with 15 µl of 40 mM mBrB and brought to a pH of 8.0 114 
using 20 µL of 2 M Tris. After a 10-min incubation in the dark, samples were acidified with 1% (v/v, 115 
final concentration) HCl and loaded onto HPLC. HPLC separation was performed on a C18 column 116 
(Zorbax Eclipse XDB-C18, 4.6 mm 150 mm, 5 mm, Agilent Technologies). Elution conditions were 117 
as follows: solvent A, sodium acetate 0.25% (v/v), pH 3.09; solvent B, acetonitrile; 0–5 min, 94% 118 
solvent A/6% solvent B; 5–10 min linear gradient from 6% to 100% solvent B. A constant flow rate 119 
of 1.2 mL/min was applied. Detection was performed at 390 nm excitation and at 480 nm emission 120 
wavelengths [15]. All measurements were carried out with an Agilent series 1100 HPLC.  121 
PTI was calculated as the molar ratio between total S-thiolated proteins (RSSP, where RS is 122 
usually cysteine, cysteinylglycine, homocysteine, γ-glutamylcysteine and glutathione) and the 123 
concentration of free, DTNB-titrable protein thiol groups [15]. 124 
6 
2.8 Patients’ health questionnaires 125 
In SONIA2, quality of life of AKU patients was assesses through the following validated 126 
questionnaires: 127 
 Knee injury and Osteoarthritis Outcome Score (KOOS), evaluating both short- and long-128 
term consequences of knee injury. It holds 42 items in five separately scored subscales 129 
[pain, other symptoms, function in daily living, function in sport and recreation, and knee-130 
related quality of life (QoL)]. Scores are normalized to a “0–100” scale, with “0” representing 131 
extreme knee problems and “100” representing no knee problems. 132 
 Health Assessment Questionnaire (HAQ), including a disability index (haqDI) and a global 133 
pain visual analog scale (hapVAS). Eight categories are assessed: dressing and grooming, 134 
arising, eating, walking, hygiene, reach, grip, common daily activities. Results are scored 135 
from 0 (no difficulties) to 3 (unable to do). 136 
 Short Form-36 (SF-36), a multi-purpose short-form with 36 questions addressing both 137 
physical and mental status that measures patients’ QoL across eight domains: vitality, 138 
physical functioning, bodily pain, general health perception, physical role functioning, social 139 
functioning, emotional role functioning, mental health. A score of “0” indicates maximum 140 
disability, while a score of “100” indicates no disability. 141 
 AKUSSI, which incorporates multiple, clinically meaningful AKU outcomes combined with 142 
medical photography imaging investigations, and detailed questionnaires into a single score 143 
[4]. In this work, we limited to non-spine rheumatology (pain in 14 joints) and spine 144 
rheumatology (pain in four clinical spine regions) scores, expressed as percentages. 145 
These scores were used to undertake correlation analyses with the measured markers, as detailed 146 
below. 147 
2.9 Statistical analysis 148 
Results were processed through Excel and GraphPad 6.0. Normal distribution was analysed with 149 
D’Agostino-Pearson or Shapiro Wilk test depending on sample size, and summary statistics was 150 
7 
obtained for each analysed dataset. Mann-Whitney, Kruskal-Wallis followed by Dunn’s multiple 151 
comparisons, and Spearman’s rank correlation analysis were used as appropriate. 152 
 153 
3 Results 154 
The overall aim of this work was to assess baseline levels of established biomarkers related to 155 
inflammation and oxidative stress in serum from alkaptonuric patients who were/are enrolled in 156 
DevelopAKUre clinical trials. The tested biomarkers included well-known mediators of inflammatory 157 
responses (IL-6, IL-1β, TNFα and CRP) and SAA, which play also a role in inflammation, oxidative 158 
stress, and secondary (AA) amyloidosis. Serum levels of the following biomarkers were also 159 
tested: cathepsin D (CATD), a lysosomal aspartic protease taking part in intracellular digestion of 160 
proteoglycan in the initial stages of osteoarticular inflammation [25] and involved in degradation of 161 
SAA, preventing amyloid deposition [26]; IL-1 receptor antagonist (IL-1ra), which is specific for 162 
preventing the activity of IL-1α and IL-1β by competing with IL-1α and IL-1β for binding to the 163 
ligand-binding chain, termed type I (IL-1RI); metalloproteinase 3 (MMP-3), which is involved in 164 
extracellular matrix remodelling and whose serum levels are increased in inflammatory rheumatic 165 
diseases [27]. 166 
AOPP were tested as oxidative stress and potential inflammatory mediators, as they are found in 167 
several human diseases where these events are involved, such as chronic renal failure and [21, 168 
28], diabetes mellitus [29], obesity and insulin resistance [30] and their pro-inflammatory activity 169 
was demonstrated [31]. Free serum protein thiols (PSH), S-thiolated proteins, and PTI were 170 
measured to assess oxidative stress. 171 
3.1 SONIA1 172 
The majority of AKU patients (23/40; 57.5%) enrolled in SONIA1 presented with SAA levels above 173 
the reference threshold of 10 mg/L [32]; conversely, only a minority (7/40; 17.5%) had CRP levels 174 
above the reference limit (Table 1). All the other tested inflammatory markers were not statistically 175 
different (CATD, IL-1ra, TNFα, and MMP-3) or were slightly lower in AKU (IL-1β, P=0.011 and IL-6, 176 
P=0.046) compared to a control age-matched healthy population (Table 1). Routinely assessed 177 
8 
hematological parameters such as: glucose, cystatin C, alkaline phosphatase (data not shown), 178 
cholesterol, tryglicerides and LDL-cholesterol (Table 3S) were generally in range, whereas HDL-179 
cholesterol scored below the reference range in 90% of the tested AKU subjects (Table 3S). 180 
[suggested position for Table 1] 181 
The possible dependence of the tested inflammatory biomarkers from age, BMI, smoking and 182 
drinking habits, gender and site of sample collection was evaluated. No differences according to 183 
gender or cigarette smoking habits could be highlighted (Table 2). As for the other confounding 184 
factors, we found that CATD serum levels were significantly increased in subjects drinking alcohol 185 
(P<0.0001) and that IL-1ra, TNFα and CRP serum levels were higher in overweight/obese subjects 186 
compared to those with a normal BMI (Table 2). Interestingly, there were also some biomarkers 187 
that showed a different distribution according to the clinical site: CATD (P<0.0001), IL-1β 188 
(P=0.005) and MMP-3, (P<0.0001). Since AKU patients enrolled in Liverpool were from different 189 
European nations, a common trait in different lifestyle or eating habits explaining such a difference 190 
could not be identified yet [33]. Due to the chronic and progressive nature of AKU, several AKU 191 
patients enrolled in SONIA1 presented with concomitant pathologies and/or reported the use of 192 
concomitant medications. The possible effect of such concomitant medications on the levels of the 193 
tested biomarkers was ruled out (Figure 1S). A positive and significant correlation was found for 194 
SAA and CRP (Table 3), and several inflammatory biomarkers were positively correlated to BMI 195 
(SAA, IL-6, IL-1ra, TNFα and CRP). Conversely, none of the tested biomarkers was correlated to 196 
serum HGA levels (Table 3). 197 
[suggested position for Table 2 and Table 3] 198 
3.2 SONIA2 199 
SAA was the only marker, among those tested in SONIA1, that was measured also in SONIA2. 200 
Chitotriosidase activity was included as an additional marker of non-infectious inflammation [34]. 201 
Since increased AOPP [13] and PTI [15] were reported previoulsy in smaller cohorts of AKU 202 
patients, AOPP, thiols, S-thiolated proteins and PTI were investigated in SONIA2. 203 
AOPP ranged between 1.60-60.12 µmol/dL chloramine T equivalents (mean 12.45 ± 8.57 µmol/dL) 204 
and were above the reference value (set at 30 µmol/dL) in six out of the 138 analysed samples 205 
9 
(4%) (Figure 1A). No differences were found once AOPP were stratified according to subjects’ age 206 
(Figure 1B), sex (Figure 1C) or BMI (Figure 1D). No significant correlation was found with age 207 
(r=0.08913, P=0.2985) (Figure 1E) or BMI (r=0.1349, P=0.1146) (Figure 1F). 208 
[suggested position for Figure 1] 209 
SAA ranged between 1.5-311.9 mg/L (mean value 57.01 ± 64.80 mg/L). Interestingly, SAA serum 210 
levels ranged between 3 and 10 mg/L in 18 subjects (13%) and were above the threshold of 10 211 
mg/L [32] in 119 out of the 138 analysed samples (86%) (Figure 2A). SAA levels showed no 212 
differences once stratified according to subjects’ age (Figure 2B), or sex (Figure 2D), whereas a 213 
small but significant difference between underweight and obese AKU subjects was found. 214 
Nevertheless, similar ranges were observed for SAA in normal (3.8-311.9 mg/L), overweight (1.5-215 
305.7 mg/L) and obese (9.0-298.6 mg/L) AKU sujects (Figure 2E). SAA serum levels were also 216 
positively and significantly correlated to subjects’ BMI (r=0.3556, P<0.0001) (Figure 2F) but not 217 
age (r=0.1268, P=0.1382) (Figure 2C). 218 
[suggested position for Figure 2] 219 
Chitotriosidase activity ranged between 8.2-187 nmoL/mL/h (mean value 60.32 ± 33.87 220 
nmoL/mL/h) and was above the reference value (set at 51 nmoL/mL/h) in 72 out of the 138 tested 221 
samples (52%) (Figure 3A). Increasing chitotriosidase activity was observed stratifying patients 222 
according to their age (Figure 3B) and a positive correlation was found with age (Figure 3C). 223 
Conversely, no differences were observed according to sex (Figure 3D) or BMI classification 224 
(Figure 3E), and no correlation was found with BMI (Figure 3F). 225 
[suggested position for Figure 3] 226 
Levels of free thiols and S-thiolated proteins, ultimately combined into PTI, did not differ 227 
significantly beween control and AKU subjects (Figure 2S). However, a positive and significant 228 
correlation was found bewteen PTI and AKU subjects’ age [Figure 4(B)], and PTI values were 229 
statistically different when stratified according to age [Figure 4(A)]. Conversely, no differences 230 
were observed according to sex [Figure 4(E)] or BMI classification [Figure 4(C)], and no 231 
correlation was found between PTI and BMI [Figure 4(D)]. 232 
[suggested position for Figure 4] 233 
10 
Concomitant medications were not found to alter significantly the levels of the tested markers 234 
(Figure 3S). 235 
When inflammatory and oxidative marker levels were correlated to the outcomes of health 236 
questionnaires, we found weak but statistically significant correlations indicating that high levels of 237 
SAA were more frequently associated both to a higher degree of difficulties in sport activities as 238 
well as to a reduced perceived knee-related quality of life (KOOS questionnaire). Similarly, patients 239 
with high PTI and chitotriosidase activity reported more frequently an increased severity of pain 240 
and symptoms, difficulties in daily activities and sport, and a reduced perceived knee-related 241 
quality of life (KOOS questionnaire) (Table 4). We also found that high serum levels of SAA, PTI 242 
and chitotriosidase activity were more frequently associated to an increased perception of disability 243 
(haqDI, HAQ questionnaire) and to a reduced perceived physical health (i.e., lower levels of 244 
functioning according to SF-36) (Table 4). Higher PTI values were positively associated to pain in 245 
multiple spine regions, and higher chitotriosidase activity was positively associated to joint and 246 
spinal pain (AKUSSI questionnaire) (Table 4). Positive correlations were also found between PTI-247 
SAA (r=0.187, P=0.032) and PTI-chitotriosidase (r=0.392, P<0.0001). 248 
[suggested position for Table 4] 249 
 250 
4 Discussion 251 
Serum represents an excellent and easily accessible source of protein biomarkers that can reflect 252 
physiological/pathological conditions [35, 36]. Though AKU represents the iconic prototype “inborn 253 
error of metabolism” and shares features with other more common rheumatic diseases, it still lacks 254 
appropriate biomarkers to monitor severity and progression. Hence, this work was undertaken with 255 
the main aim of analysing levels of established biomarkers related to oxidative stress and 256 
inflammation in a large cohort of alkaptonuric patients. Due to the ultra-rarity of the disease 257 
(affecting 1:250,000-1,000,000 [1]), we were given an invaluable opportunity, as we were able to 258 
test for the very first time a high number of alkaptonuric serum specimens that were collected and 259 
stored under standardised procedures (agreed among the involved clinical centres). Our analyses 260 
were carried out at baseline, i.e. before randomisation into untreated (control) or treated-arm. 261 
11 
Confirming previous evidence from ours [6-9, 37], the major finding of this study was that SAA 262 
seemed the most promising biomarker to be assessed in AKU to monitor inflammation. SAA serum 263 
levels were significantly increased compared to reference threshold in the vast majority of samples. 264 
A similar trend was observed for another inflammatory biomarker, namely chitotriosidase, whose 265 
activity was above the reference range in half of the tested samples. These findings suggest that 266 
sub-clinical inflammation may be relevant in AKU and connected with the development of disease-267 
related complications, similarly to other rheumatic conditions where increased SAA levels can be 268 
found, such as: osteoarthritis (OA) [38], rheumatoid arthritis [39-43], Familial Mediterranean Fever 269 
(FMF) [44, 45], Juvenile Idiopathic Arthritis (JIA) [46], systemic lupus erythematosus (SLE) [43]. 270 
Conversely, serum AKU-related oxidative stress markers that were shown to be increased in 271 
smaller cohorts of AKU subjects such as AOPP [13] and PTI [15], in this work were not significantly 272 
different from a control population. 273 
Since CRP levels were increased only in a minority of the tested AKU subjects, superiority of SAA 274 
and chitotriosidase compared to CRP to monitor subclinical inflammation might be suggested in 275 
AKU. This is similar to what observed for SAA in patients suffering from FMF [44, 47, 48] and is 276 
further supported by recent works where SAA was proposed as a better biomarker than CRP to 277 
monitor rheumatic disease activity [41, 46, 49, 50] or response to pharmacological treatment [43, 278 
44, 51]. 279 
Additionally, since plasma SAA levels correlate with SAA levels in synovial fluid, passive diffusion 280 
of SAA from systemic circulation to synovial joint may be speculated [38]. This is particularly 281 
relevant due to the role that SAA might play in joint destruction through induction of 282 
metalloproteinases and collagen [41] although different functions have been suggested for 283 
systemic and locally-produced SAA isoforms, as well as for acute and constitutive SAA [41]. SAA 284 
may thus be considered a mediator of “danger signal” driving inflammatory processes in AKU. 285 
The serum concentration of SAA closely reflects the activity and severity of OA [38], FMF [44, 52], 286 
ankylosing spondylitis [50], JIA [46], polymyalgia rheumatica [53] and early RA [54, 55]. We 287 
provided evidence that AKU patients presenting with significantly higher SAA and chitotriosidase 288 
activity (enhanced inflammation) and higher PTI (enhanced oxidative stress) reported more often a 289 
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decreased quality of life (as assessed through patients’ health questionnaires) and scored higher in 290 
the AKUSSI scale for joint and spinal pain. This suggests that worsening of symptoms in AKU is 291 
paralleled by increased inflammation and oxidative stress, which might play a role in AKU 292 
progression. Consequently, SAA, chitotriosidase activity and PTI might be proposed as disease 293 
activity markers in AKU, although further evidence is needed. 294 
The positive association between SAA and BMI that we found in the tested AKU subjects is not 295 
new [41, 56-58] and might be justified by the fact that SAA is expressed both in liver and adipose 296 
tissue [56]. In particular, in obesity (where low-grade inflammation is found), adipose tissue is the 297 
major source of SAA, which can be considered an obesity-related inflammatory protein [57, 59]. It 298 
is known that HDL counter-regulates SAA and other pro-inflammatory mediators [60]. Interestingly, 299 
we found that 90% of the tested AKU subjects enrolled in SONIA1 had lower levels of HDL than 300 
what established by reference guidelines. Chronic inflammation, as outlined in FMF, RA and SLE 301 
subjects [48, 61-63] might alter the structure and functions of HDL, overall impairing HDL 302 
properties. In particular, a decreased antioxidant activity of HDL might follow displacement of 303 
ApoA-I from HDL due to high SAA. Since altered profiles in apolipoproteins were documented by 304 
comparative proteomics of AKU serum [13], this topic deserves further investigations in AKU. 305 
 306 
Reactive systemic AA amyloidosis can complicate chronic inflammatory disorders that are 307 
associated with a sustained acute phase response. AA amyloid fibrils are derived from the acute-308 
phase reactant SAA through a process of cleavage, misfolding, and aggregation into a highly 309 
ordered abnormal β-sheet conformation (amyloid) [32]. Sustained overproduction of SAA is a 310 
prerequisite for the development of AA amyloidosis [32].  311 
Persistently elevated SAA levels represent a risk factor for the development of amyloidosis due to 312 
deposition of amyloid aggregates in several organs and tissues. However, physiological and 313 
pathological functions of SAA are still partly unclear and differences between recombinant and 314 
endogenous SAA have been highlighted in in vitro assays, probably due to a difference in 315 
association to lipids [41, 59]. Pathological SAA serum levels were found to fall within a wide range 316 
in the tested AKU subjects. This finding becomes particularly relevant in the light of a very recent 317 
13 
work [64] where HGA was found to act as an amyloid aggregation enhancer in vitro (in a time- and 318 
dose- dependent fashion) for amyloidogenic proteins and peptides, such as: Aβ(1-42), 319 
transthyretin, atrial natriuretic peptide, α-synuclein and SAA. In particular, the pro-aggregating 320 
effect of HGA towards SAA was found even at nearly physiological HGA concentrations [64]. Thus, 321 
based on the results presented in this work, pharmacological control of SAA circulating levels in 322 
AKU seems appropriate to be suggested. 323 
 324 
We believe our study presents a number of strengths. Considering the rarity of the disease, the 325 
number of tested samples (nearly 200) and biomarkers is noteworthy. Furthermore, homogenous 326 
study samples were collected thanks to tight coordination between the involved clinical sites. 327 
Lastly, this was the first time that inflammatory and oxidative stress biomarkers could be 328 
investigated in vivo in AKU. Conversely, since AKU is not life-threating, the presence of 329 
concomitant pathologies or medications has to be taken into account due to the 330 
chronic/progressive nature of the disease. In this respect, it should be underlined that all the 331 
possible confounding factors collected during the studies (smoking, drinking, concomitant use of 332 
drugs) were considered in our analysis. All the data obtained within this work could hence be used 333 
to populate a dedicated database integrating biomarker levels, demographics, patient’s quality of 334 
life, environmental and life-style data, and clinical outcomes. Such a database could represent an 335 
optimal tool with potential relapses for the study of AKU and the development of a precision 336 
medicine approach for AKU and other more common rheumatic disorders [65]. 337 
 338 
In the light of data presented here showing increased serum SAA in AKU, an appropriate 339 
pharmacological treatment able to address this feature of the disease could be suggested as well. 340 
Low dose methotrexate (MTX) can down-regulate inflammation acting on several steps triggering 341 
and perpetuating inflammation [66]. In particulat, thanks to its ability to lower SAA production, MTX 342 
at low dosages is the anchor drug to treat rheumatic diseases and the associated AA amyloidosis 343 
[32, 67, 68]. Control of the acute phase response is currently the standard of care in amyloidosis 344 
and rheumatic disorders [32, 69]. Efficacy of low dose MTX in lowering several inflammatory 345 
14 
mediators in serum or synovial fluid of RA patients can be observed, associated with prolonged 346 
survival, reversal of amyloid deposition and recovery of organ function when SAA concentration 347 
are kept below 10 mg/L [55, 70]. 348 
 349 
5 Conclusions 350 
Increased SAA and chitotriosidase activity were detected in the vast majority of AKU samples, 351 
indicating increased systemic inflammation. Conversely, oxidative stress biomarkers were not 352 
significantly different when compared to a normal population. SAA, but especially PTI and 353 
chitotriosidase activity were correlated to AKU severity, as assessed through validated health 354 
questionnaires and AKUSSI, indicating a role for both oxidative stress and inflammation in AKU 355 
progression and severity. Prospectively, routine assessment of SAA should be recommended in 356 
AKU so that proper interventions could be put in place to address the inflammatory-pro-357 
amyloidogenic component of the disease. This is particularly relevant in view of the recent in vitro 358 
reports indicating that even nearly physiological HGA concentrations might enhance SAA 359 
aggregation [64]. 360 
  361 
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Figure legends 
Figure 1: AOPP serum levels (expressed as µmoL/dL chloramine T equivalents) at baseline in 
SONIA2 subjects. M: males; F: females; U: underweight; N: normal; OW: overweight; O: obese. 
Figure 2: SAA serum levels (mg/L) at baseline in SONIA2 subjects. M: males; F: females; U: 
underweight; N: normal; OW: overweight; O: obese. 
Figure 3: Chitotriosidase activity (nomL/mL/h) at baseline in SONIA2 subjects. M: males; F: 
females; U: underweight; N: normal; OW: overweight; O: obese. 
Figure 4: PTI values at baseline in SONIA2 subjects. M: males; F: females; U: underweight; N: 
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Table 1: SONIA1 inflammatory markers. Data are expressed as mean±stdev 
 






59.01±35.95 146.4±115.2 1.674±0.510 4.604±0.908 4.874±0.964 CRP≥5 
n=7 (17.5%) 
11.29±5.654 
CTR nd 46.68±5.881 81.29±19.25 1.774±0.101 4.927±0.133 5.109±2.653 nd 13.15±4.823 
P value na 0.551 0.093 ** 0.011 * 0.046 0.546 na 0.642 
na: not applicable; nd: not determined 
 
Table 1
Table 2: SONIA1 inflammatory markers according to gender, BMI classification, patients’ smoking 
and drinking habits, and clinical site. Data are expressed as mean±stdev. 
 










CRP (mg/L) MMP-3 
(ng/mL) 
gender male 25.71±40.33 64.99±36.95 146.7±108.5 1.686±0.555 4.874±0.964 4.721±0.882 1.830±2.023 12.41±5.85 
 female 53.25±56.81 47.06±31.88 145.9±132.6 1.648±0.418 5.109±2.653 5.191±1.083 3.988±5.621 8.98±4.60 
 
 
P value 0.082 0.075 0.829 0.881 0.286 0.226 0.316 0.059 
BMI normal 26.08±34.73 55.37±29.89 95.89±32.27 1.692±0.533 4.695±1.287 4.491±0.892 1.295±1.652 11.32±5.99 
 overweight 42.30±65.20 55.76±32.87 114.7±46.59 1.542±0.266 4.513±0.603 4.713±0.841 3.143±5.207 10.60±4.84 







(N vs. OW) 
(N vs. O) 



































yes 26.68±31.15 80.00±37.38 177.1±141.5 1.692±0.536 4.550±0.969 4.777±0.905 1.949±1.898 12.01±6.21 
 no 41.89±58.27 41.02±23.06 118.6±78.39 1.657±0.497 4.653±0.870 4.961±0.991 3.058±4.739 8.29±5.17 
 
 
P value 0.507 **** <0.0001 0.078 0.170 0.673 0.507 0.802 0.533 
smoker yes 37.68±62.41 66.26±30.99 155.1±101.3 1.775±0.691 4.413±0.318 5.004±0.999 2.600±2.731 13.18±6.69 
 no 33.78±43.37 56.84±37.52 143.9±120.3 1.644±0.454 4.659±1.015 4.836±0.967 2.511±3.944 10.74±5.32 
 
 
P value 0.903 0.255 0.424 0.615 0.508 0.479 0.678 0.371 
clinical 
site 
UK 30.56±27.74 92.22±35.21 167.3±119.4 1.888±0.672 4.634±1.058 4.767±0.980 1.927±1.874 16.09±5.86 
 SK 37.12±56.46 40.42±19.27 133.9±113.1 1.545±3.336 4.586±0.828 4.938±0.969 2.894±4.418 8.41±2.98 
 
 
P value 0.379 ****<0.0001 0.132 ** 0.005 0.940 0.539 0.814 ****<0.0001 
ns: not significant 
 
Table 2
Table 3: Correlation matrix for inflammatory markers measured in SONIA1 study. Spearman’s rank 
correlation analysis was carried out; r and P values are reported. 
 
 
 CATD IL-6 IL-1β IL-1ra TNFα CRP MMP-3 age BMI HGA cholesterol triglycerides HDL LDL 
SAA r 0.148 0.0450 0.135 0.257 0.066 0.604 0.108 0.351 0.344 0.030 0.362 0.073 0.209 0.336 
 P 0.369 0.783 0.407 0.109 0.684 **** <0.0001 0.508 * 0.026 * 0.030 0.854 * 0.022 0.653 0.195 * 0.034 
CATD r  -0.163 0.191 0.226 -0.101 -0.003 0.392 -0.0213 -0.006 0.270 0.181 -0.317 0.173 0.188 
 P  0.320 0.243 0.166 0.541 0.987 * 0.014 0.193 0.970 0.097 0.269 * 0.049 0.293 0.252 
IL-6 r  
 
0.187 0.466 0.203 0.166 -0.005 0.287 0.350 0.256 -.0164 -0.064 -0.079 -0.073 
 P   0.249 *** 0.002 0.208 0.305 0.975 0.073 * 0.027 0.111 0.312 0.696 0.629 0.657 
IL-1β r  
  
0.217 0.232 -0.047 0.197 -0.133 0.136 0.213 -0.020 -0.054 0.056 -0.030 
 P    0.178 0.150 0.775 0.224 0.413 0.402 0.187 0.904 0.743 0.732 0.855 
IL-1ra r    
 
0.121 0.439 0.226 0.059 0.467 0.121 -0.044 0.008 -0.221 -0.002 
 P     0.457 ** 0.005 0.160 0.716 *** 0.002 0.456 0.788 0.962 0.171 0.989 
TNFα r      0.028 -0.025 0.056 0.429 0.258 -0.257 0.099 -0.290 -0.219 
 P      0.863 0.876 0.734 ** 0.006 0.108 0.110 0.544 0.069 0.174 
CRP r      
 
-0.070 0.358 0.485 -0.030 0.098 0.269 -0.147 0.117 
 P       0.668 * 0.023 *** 0.001 0.856 0.548 0.093 0.366 0.471 
MMP-3 r        0.144 0.012 0.225 0.172 -0.052 -0.027 0.188 
 P        0.374 0.941 0.163 0.289 0.750 0.867 0.244 
age r        
 
0.301 0.032 0.330 0.184 0.138 0.282 
 P         0.059 0.844 * 0.037 0.256 0.396 0.078 
BMI r          0.394 -0.267 0.270 -0.503 -0.205 
 P          * 0.012 0.096 0.092 ***0.001 0.204 
HGA r           -0.143 -0.099 -0.249 -0.008 
 P           0.379 0.542 0.122 0.959 
cholesterol r            0.144 0.400 0.918 
 P            0.375 ** 0.01 **** <0.0001 
triglycerides r             -0.509 0.004 
 P             ***0.001 0.979 
HDL r              0.284 
 P              0.076 
 
Table 3




 KOOS HAQ SF-36 AKUSSI 
  pain symptoms activity of daily living sport QoL hapVAS haqDI physical mental joint pain spinal pain 
AOPP r 0.043 0.054 0.048 -0.022 -0.040 -0.082 0.077 -0.042 -0.039 0.056 -0.024 
 P 0.624 0.537 0.584 0.809 0.650 0.340 0.367 0.627 0.655 0.512 0.784 
SAA r -0.132 -0.134 -0.169 -0.177 -0.226 0.084 0.209 -0.137 -0.137 0.091 0.057 
 P 0.129 0.123 0.051 * 0.044 ** 0.009 0.329 * 0.015 ** 0.006 0.111 0.288 0.510 
CHITOTRIOSIDASE r -0.314 -0.273 -0.303 -0.367 -0.330 0.055 0.336 -0.181 -0.076 0.244 0.228 
 P *** 0.0003 ** 0.002 *** 0.0004 **** <0.0001 *** 0.0001 0.531 **** <0.0001 * 0.038 0.387 ** 0.004 ** 0.008 
PTI r -0.190 -0.265 -0.199 -0.312 -0.288 0.129 0.350 -0.228 -0.024 0.104 0.220 
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